Cited by 1,322Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies ResearchChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Open access

Lonial, Sagar, Dimopoulos, Meletios, Palumbo, Antonio, White, Darrell, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Moreau, Philippe, Mateos, Maria-Victoria, Magen, Hila, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z., Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Wu, Ka Lung, Singhal, Anil, San-Miguel, Jesus, Matsumoto, Morio, Katz, Jessica, Bleickardt, Eric, Poulart, Valerie, Anderson, Kenneth C., Richardson, Paul·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1505654

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1505654

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
SLAM Family Receptors and SAP Adaptors in Immunity
Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citation
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citation
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Collins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202
Self-citation
EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization
Pérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 93

Flagged first, then by citations

Show all 15 references

Sorted by citations

Items 601–700 of 1,000

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Nishihori, T., Song, J., & Shain, K. H. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0308-3 · Cited by 15
The role of SLAMF7 in multiple myeloma: impact on therapy
Boudreault, J., Touzeau, C., & Moreau, P. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1209112 · Cited by 15
Self-citation
Multiple myeloma: managing a complex blood cancer
Dowling, M., Kelly, M. L., & Meenaghan, T. (2016) · British Journal of Nursing · doi:10.12968/bjon.2016.25.s18 · Cited by 15
Publishing interim results of randomised clinical trials in peer-reviewed journals
Counsell, N., Biri, D., Fraczek, J., & Hackshaw, A. K. (2016) · Clinical Trials · doi:10.1177/1740774516664689 · Cited by 15
Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
Suzuki, K., Ri, M., Chou, T., Sugiura, I., Takezako, N., Sunami, K., Ishida, T., Izumi, T., Ozaki, S., Shumiya, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13166 · Cited by 15
A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
Dispenzieri, A. A., D’Souza, A., Gertz, M. A., Laumann, K. M., Wiseman, G. A., Lacy, M. Q., LaPlant, B. R., Buadi, F. K., Hayman, S. R., Kumar, S. K., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.164 · Cited by 15
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum
Kansai Myeloma Forum Investigators, Matsumura‐Kimoto, Y., Kuroda, J., Kaneko, H., Kamitsuji, Y., Fuchida, S., Nakaya, A., Shibayama, H., Uoshima, N., Yokota, I., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2416-4 · Cited by 15
Management of Multiple Myeloma
Kumar, S. K. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0040 · Cited by 15
Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy
Suzuki, A., Kakugawa, S., Miyoshi, M., Hori, M., Suzuki, K., Furukawa, Y., & Ohta, K. (2020) · Leukemia · doi:10.1038/s41375-020-0860-7 · Cited by 15
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Bonello, F., Grasso, M., D’Agostino, M., Celeghini, I., Castellino, A., Boccadoro, M., & Bringhen, S. (2020) · Pharmaceuticals · doi:10.3390/ph14010020 · Cited by 17
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 17
Multiple myeloma
Chavda, S. J., & Yong, K. (2017) · British Journal of Hospital Medicine · doi:10.12968/hmed.2017.78.2.c21 · Cited by 15
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
Onda, Y., Kanda, J., Kaneko, H., Shimura, Y., Fuchida, S., Nakaya, A., Itou, T., Yamamura, R., Tanaka, H., Shibayama, H., et al. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221104584 · Cited by 15
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
Sobh, M., Michallet, M., Dubois, V., Iacobelli, S., Köster, L., van Biezen, A., Fegueux, N., Tabrizi, R., Finke, J., Cheikh, J. E., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.165399 · Cited by 15
Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors
Pavlova, A., Maschan, M. A., & Ponomarev, V. (2017) · Oncohematology · doi:10.17650/1818-8346-2017-12-1-17-32 · Cited by 15
Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?
Golay, J. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.002 · Cited by 15
Elotuzumab in multiple myeloma
Bruzzese, A., Martino, E. A., Vigna, E., Iaccino, E., Mendicino, F., Lucia, E., Olivito, V., Filippelli, G., Neri, A., Morabito, F., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2145882 · Cited by 15
Immunomodulatory Agents for Multiple Myeloma
Minařík, J., & Ševčı́ková, S. (2022) · Cancers · doi:10.3390/cancers14235759 · Cited by 17
Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Martin, T. G., Shah, N. D., Richter, J. R., Vesole, D. H., Wong, S. W. K., Huang, C., Madduri, D., Jagannath, S., Siegel, D. S. D., Biran, N., et al. (2021) · Cancer · doi:10.1002/cncr.33448 · Cited by 14
Recent advances in the diagnosis and management of amyloid cardiomyopathy
Nijst, P., & Tang, W. H. W. (2021) · Faculty Reviews · doi:10.12703/r/10-31 · Cited by 14
Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells
Edri, A., Haim, N. B., Hailu, A., Brycman, N., Berhani-Zipori, O., Rifman, J., Cohen, S., Yackoubov, D., Rosenberg, M., Simantov, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417231 · Cited by 14
Self-citation
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 16
Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies
Schindler-Wnek, K., Stahringer, A., Heimer, N., Koehl, U., Fricke, S., & Schmiedel, D. (2025) · Oncoimmunology · doi:10.1080/2162402x.2025.2546443 · Cited by 12
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
Larsen, J. T., & Kumar, S. K. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0009-4 · Cited by 14
New Targets and New Agents in High-Risk Multiple Myeloma
Nooka, A. K., & Lonial, S. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159516 · Cited by 14
Self-citation
Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma
Faiman, B. M., Doss, D. S., Colson, K., Mangan, P. A., King, T., Tariman, J. D., & and Board (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s5.19-36 · Cited by 14
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Lamb, Y. N. (2018) · Drugs · doi:10.1007/s40265-018-0969-4 · Cited by 14
Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland
Mankinen, P., Vihervaara, V., Torvinen, S., Martikainen, J. A., & Soini, E. J. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1569457 · Cited by 14
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Lin, H. M., Davis, K. L., Kaye, J. A., Luptakova, K., Nagar, S. P., & Mohty, M. (2019) · Advances in Hematology · doi:10.1155/2019/4625787 · Cited by 14
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Parisi, M. S., Leotta, S., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Giubbolini, R., Markovic, U., Leotta, V., Giorgio, M. A. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101695 · Cited by 14
Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them
Chhabra, S., Szabó, A., Glisch, C., George, G., Narra, R. K., Harrington, A. M., Jerkins, J. H., D’Souza, A., Dhakal, B., Pasquini, M. C., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.02.020 · Cited by 14
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Hose, D., Schreder, M., Hefner, J., Bittrich, M., Danhof, S., Strifler, S., Krauth, M., Schoder, R., Gisslinger, B., Einsele, H., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03323-6 · Cited by 14
Self-citation
Monoclonal antibodies in multiple myeloma
Vozella, F., Fazio, F., Lapietra, G., Petrucci, M. T., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04149-x · Cited by 14
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Ray, U., & Orlowski, R. Z. (2023) · Pharmaceuticals · doi:10.3390/ph16040590 · Cited by 17
Self-citation
Analysis of Updates in Multiple Myeloma Treatment and Management
Nieto, M. J., Hedjar, A., Locke, M., Caro, J., & Saif, M. W. (2023) · Journal of Clinical Haematology · doi:10.33696/haematology.4.055 · Cited by 14
Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis
Miyazaki, K., & Suzuki, K. (2016) · Amyloid · doi:10.1080/13506129.2016.1232647 · Cited by 14
Practical Considerations in Managing Relapsed Multiple Myeloma
Agarwal, A., Chow, E., Bhutani, M., Voorhees, P. M., Friend, R. N., & Usmani, S. Z. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.010 · Cited by 15
Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
Suzuki, K., Sunami, K., Ohashi, K., Iida, S., Mori, T., Handa, H., Matsue, K., Miyoshi, M., Bleickardt, E. W., Matsumoto, M., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.18 · Cited by 14
Self-citation
Which therapies will move to the front line for multiple myeloma?
Cejalvo, M. J., & de la Rubia, J. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1317589 · Cited by 15
Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era
Klener, P., Etrych, T., & Klener, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171006144725 · Cited by 14
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against
Richardson, P. G. G., Holstein, S. A., Schlossman, R. L., Anderson, K. C., Attal, M., & McCarthy, P. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409207 · Cited by 14
Self-citation
Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development
Teng, Z., Gupta, N., Hua, Z., Liu, G., Samnotra, V., Venkatakrishnan, K., & Labotka, R. (2017) · Clinical and Translational Science · doi:10.1111/cts.12524 · Cited by 14
Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma
Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8501 · Cited by 14
Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Kint, N., & Delforge, M. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.08.001 · Cited by 14
ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
Lath, D., Buckle, C., Evans, H., Fisher, M., Down, J. M., Lawson, M. A., & Chantry, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199517 · Cited by 14
Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma
Le, G. N., Bones, J., Coyne, M., Bazou, D., Dowling, P., O’Gorman, P., & Larkin, A. (2019) · Molecular Omics · doi:10.1039/c8mo00193f · Cited by 16
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
Barbieri, E., Martino, E. A., Rivolti, E., Quaresima, M., Vigna, E., Neri, A., Morabito, F., & Gentile, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2357382 · Cited by 13
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Korst, C. L. B. M., O’Neill, C. A., Bruins, W. S. C., Cosovic, M., Twickler, I., Verkleij, C. P. M., Clerre, D. L., Themeli, M., Chion-Sotinel, I., Zweegman, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008769 · Cited by 13
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Moreau, P., Facon, T. T. F., Usmani, S. Z., Bahlis, N. J., Raje, N. S., Plesner, T., Orlowski, R. Z., Basu, S., Nahi, H., Hulin, C., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02506-1 · Cited by 13
Self-citation
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Weisel, K. C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94531 · Cited by 13
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma
Berenson, J. R., Manges, R., Badarinath, S., Cartmell, A., McIntyre, K. J., Lyons, R. M., Harb, W. A., Mohamed, H., Nourbakhsh, A., & Rifkin, R. M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24687 · Cited by 13
Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
Liu, J., Yang, H. J., Liang, X., Wang, Y., Hou, J., Liu, Y., Wang, J., & Zhou, F. (2017) · Oncotarget · doi:10.18632/oncotarget.18722 · Cited by 13
Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies
Rotolo, A., Karadimitris, A., & Ruella, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1403024 · Cited by 15
Maintenance and continuous therapy for multiple myeloma
Richardson, P. G. G., Laubach, J. P., Gandolfi, S., Facon, T. T. F., Weisel, K. C., & O’Gorman, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1490181 · Cited by 13
Self-citation
Seeking Convergence and Cure with New Myeloma Therapies
Choudhry, P., Galligan, D. C., & Wiita, A. P. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.005 · Cited by 13
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
Cope, S. F., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M., Weisel, K. C., & Jansen, J. P. (2020) · Value in Health · doi:10.1016/j.jval.2019.11.003 · Cited by 13
Self-citation
Primary refractory multiple myeloma: a real-world experience with 85 cases
Jurczyszyn, A. J., Waszczuk‐Gajda, A., Castillo, J. J., Krawczyk, K., Štork, M., Pour, L., Usnarska‐Zubkiewicz, L., Potoczek, S., Hus, I., Dávila, J., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1788014 · Cited by 13
Belantamab Mafodotin in the Treatment of Relapsed or Refractory Multiple Myeloma
Sheikh, S., Lebel, E., & Trudel, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0521 · Cited by 13
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Danhof, S., Rasche, L., Mottok, A., Steinmüller, T., Zhou, X., Schreder, M., Kilian, T., Strifler, S., Rosenwald, A., Hudecek, M., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04447-6 · Cited by 13
Self-citation
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Braunstein, M. J., Weltz, J., & Davies, F. E. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1909469 · Cited by 13
Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
Jeryczynski, G., Bolomsky, A., Agis, H., & Krauth, M. (2021) · Cancers · doi:10.3390/cancers13235886 · Cited by 13
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells
Panaampon, J., Kariya, R., & Okada, S. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03177-6 · Cited by 13
Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma
Tsukamoto, T., Kinoshita, M., Yamada, K., Ito, H., Yamaguchi, T., Chinen, Y., Mizutani, S., Fujino, T., Kobayashi, T., Shimura, Y., et al. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01136-2 · Cited by 13
New Strategies for the Treatment of Older Myeloma Patients
Larocca, A., Cani, L., Bertuglia, G., Bruno, B., & Bringhen, S. (2023) · Cancers · doi:10.3390/cancers15102693 · Cited by 14
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
Kauer, J., Freundt, E. P., Schmitt, A., Weinhold, N., Mai, E. K., Müller‐Tidow, C., Goldschmidt, H., Raab, M. S., Kriegsmann, K., & Sauer, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11507-9 · Cited by 13
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
Pianko, M. J., Funt, S. A., Page, D. B., Cattry, D., Scott, E. C., Ansell, S. M., Borrello, I., Gutiérrez, M., Lendvai, N. K., Hassoun, H., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1320713 · Cited by 13
Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case
Djatche, L. M., Goble, J. A., Chun, G., & Varga, Š. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.1.39 · Cited by 13
Practical Considerations for Antibodies in Myeloma
Laubach, J. P., van de Donk, N. W. C. J., Davies, F. E., & Mikhael, J. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_205443 · Cited by 13
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
Zheng, Y., Shen, H.-Y., Xu, L., Feng, J., Tang, H., Zhang, N., Chen, X., & Gao, G. (2018) · Journal of Immunology Research · doi:10.1155/2018/7646913 · Cited by 13
Therapeutic antibodies for multiple myeloma
Ishida, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy133 · Cited by 13
A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma
Hollmann, S., Moldaver, D., Goyert, N., Grima, D. T., & Maiese, E. M. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.4.449 · Cited by 13
Emerging drugs for the treatment of light chain amyloidosis
Chakraborty, R., & Lentzsch, S. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1803829 · Cited by 14
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial
Lee, J. H., Park, Y., Kang, K., Lee, J., Lee, H. S., Eom, H., Do, Y. R., Kim, J. S., Yoon, S., Shin, D., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04407-0 · Cited by 13
Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies
Böttcher, S. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9151-8_8 · Cited by 13
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
Handa, H., Ishida, T., Ozaki, S., Mori, A., Kato, K., & Iida, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283931 · Cited by 12
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies
Jureczek, J., Kałwak, K., & Dzięgiel, P. (2024) · Cancers · doi:10.3390/cancers16244181 · Cited by 12
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Mettias, S., ElSayed, A., Moore, J., & Berenson, J. R. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01122-4 · Cited by 12
Daratumumab in multiple myeloma
Rajkumar, S. V. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01226-x · Cited by 12
Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
Fancher, K. M., & Bunk, E. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.5.6 · Cited by 12
The next generation of novel therapies for the management of relapsed multiple myeloma
Gonsalves, W. I., Milani, P., Derudas, D., & Buadi, F. K. (2016) · Future Oncology · doi:10.2217/fon-2016-0200 · Cited by 12
Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
Chen, W.-C., Kanate, A. S., Craig, M., Petros, W. P., & Hazlehurst, L. (2017) · Cancer Management and Research · doi:10.2147/cmar.s117477 · Cited by 12
Multiple Liver Nodules Mimicking Metastatic Disease as Initial Presentation of Multiple Myeloma
Tiu, A. C., Potdar, R. R., Arguello-Guerra, V., & Morginstin, M. S. (2018) · Case Reports in Hematology · doi:10.1155/2018/7954816 · Cited by 12
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease
Kyriazoglou, A. I., Ntanasis‐Stathopoulos, I., Terpos, E., Fotiou, D., Kastritis, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.620 · Cited by 12
Self-citation
Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
Giuliani, M., & Poggi, A. D. (2020) · Cells · doi:10.3390/cells9071578 · Cited by 13
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review
Sanchez, L. J., Barley, K. M., Richter, J. R., Franz, J. K., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., & Chari, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1804356 · Cited by 12
Genetic Predictors of Mortality in Patients with Multiple Myeloma
Hassan, H., & Szalat, R. E. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s262866 · Cited by 12
Expression of activated integrin β7 in multiple myeloma patients
Hosen, N., Yoshihara, S., Takamatsu, H., Ri, M., Nagata, Y., Kosugi, H., Shimomura, Y., Hanamura, I., Fuji, S., Minauchi, K., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03162-2 · Cited by 13
Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials
Tao, Y., Zhou, H., & Niu, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.758992 · Cited by 12
Targeting plasma cells: are we any closer to a panacea for diseases of antibody‐secreting cells?
Low, M. S. Y., Infantino, S., Grigoriadis, G., & Tarlinton, D. M. (2016) · Immunological Reviews · doi:10.1111/imr.12388 · Cited by 13
Determining treatment intensity in elderly patients with multiple myeloma
Salvini, M., D’Agostino, M., Bonello, F., Boccadoro, M., & Bringhen, S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1496823 · Cited by 12
Moving Toward Continuous Therapy in Multiple Myeloma
Bonello, F., Cetani, G., Bertamini, L., Gay, F., & Larocca, A. (2019) · Clinical Hematology International · doi:10.2991/chi.d.191101.001 · Cited by 13
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
Maruyama, D., Iida, S., Ogawa, G., Fukuhara, N., Seo, S., Miyazaki, K., Yoshimitsu, M., Kuroda, J., Tsukamoto, N., Tsujimura, H., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16878 · Cited by 12
CD38 targeted treatment for multiple myeloma
Jelı́nek, T., Mihályová, J., & Hájek, R. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.131 · Cited by 12
When and How to Treat Relapsed Multiple Myeloma
Nathwani, N., Bertamini, L., Banerjee, R. K., Gay, F., Shah, N. D., & Krishnan, A. Y. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320129 · Cited by 14
Drug resistance and minimal residual disease in multiple myeloma
Gozzetti, A., Ciofini, S., Sicuranza, A., Pacelli, P., Raspadori, D., Cencini, E., Tocci, D., & Bocchia, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.116 · Cited by 12
Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches
Szalat, R. E., & Munshi, N. C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159017 · Cited by 12
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
Offidani, M., Boccadoro, M., Raimondo, F. D., Petrucci, M. T., Tosi, P., & Cavo, M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00507-x · Cited by 12
MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1
Xu, K., Hu, X., Sun, L., Liang, Q., Ouyang, G., Zhang, Y., Mu, Q., & Yan, X. (2019) · Human Cell · doi:10.1007/s13577-019-00276-y · Cited by 12
Antibody-Based Treatment Approaches in Multiple Myeloma
Hosoya, H., & Sidana, S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00624-6 · Cited by 12
The extended 4-year follow-up results of the ELOQUENT-2 trial
Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2019) · Oncotarget · doi:10.18632/oncotarget.26527 · Cited by 12
Self-citation

Authors: Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K. L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C., & Richardson, P.
Affiliations: Dalhousie University (CA)
National and Kapodistrian University of Athens (GR)
Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
Medical University of Silesia (PL)
Centre Hospitalier Universitaire de Nantes (FR)
Tel Aviv University (IL)
University of Alberta (CA)
Princess Margaret Cancer Centre (CA)
Alfred Health (AU)
Barts Health NHS Trust (GB)
The University of Texas MD Anderson Cancer Center (US)
Kyoto Prefectural University of Medicine (JP)
Technische Universität Dresden (DE)
Universitätsklinikum Würzburg (DE)
Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
AbbVie Biotherapeutics (United States) (US)
National Hospital Organization (JP)
Bristol-Myers Squibb (United States) (US)
Dana-Farber Cancer Institute (US)
ORCID: Lonial, Sagar
Dimopoulos, Meletios
Palumbo, Antonio
White, Darrell
Grosicki, Sebastian
Moreau, Philippe
Magen, Hila
Belch, Andrew
Reece, Donna
Spencer, Andrew
Orlowski, Robert Z.
Röllig, Christoph
Einsele, Hermann
Wu, Ka Lung
Bleickardt, Eric
Anderson, Kenneth C.
Richardson, Paul
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-08-13
Volume: 373
Issue: 7
Pages: 621-631
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1505654
OpenAlex: W2201190784
Semantic Scholar: fb9d8d9019089b66fbe8ecd85963014c537e649e
Cited by: 1,322
References: 15
Citations by year: 2026: 29 · 2025: 60 · 2024: 63 · 2023: 87 · 2022: 95 · 2021: 147 · 2020: 174 · 2019: 132 · 2018: 154 · 2017: 187 · 2016: 160 · 2015: 33
FWCI: 139.84
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders: Bristol-Myers Squibb
AbbVie Biotherapeutics
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords: elotuzumab, relapsed/refractory multiple myeloma, SLAMF7, lenalidomide, dexamethasone, progression-free survival, overall response rate, monoclonal antibodies, combination therapy, adverse events, lymphopenia, neutropenia, infusion reactions, interim analysis, overall survival
MeSH terms: Signaling Lymphocytic Activation Molecule Family, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Receptors, Immunologic, Recurrence, Thalidomide, Disease-Free Survival, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks